ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Serono Bolsters New Drug Pipeline

October 23, 2006 | APPEARED IN VOLUME 84, ISSUE 43

Serono has licensed a late-stage drug for cognitive disorders from Italian R&D firm Newron Pharmaceuticals. Serono will pay Newron up to $200 million in up-front payments and milestones for access to safinamide, an α-aminoamide derivative that is currently in Phase III trials for Parkinson's disease. The Swiss biotech firm will also fund all future development and marketing costs for the small-molecule drug. Newron retains the right to copromote the drug in Italy and Spain.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment